Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Spousal bereavement after fibrotic interstitial lung disease: A qualitative study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Differentiation of adult severe asthma from difficult-to-treat asthma - Outcomes of a systematic assessment protocol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Self-reported intake of fruit and vegetables and risk of chronic obstructive pulmonary disease: A nation-wide twin study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Validation of ATS clinical practice guideline cut-points for FeNO in asthma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Uafklaret dyspnø.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hjertesygdomme

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiForskningpeer review

  3. Exercise cardiovascular magnetic resonance imaging allows differentiation of low-risk pulmonary arterial hypertension

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Microfibrillar-associated protein 4 (MFAP4) is a matricellular glycoprotein that co-localises with elastic fibres and is highly expressed in the lungs. The aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD).

METHODS: pMFAP4 was measured by an AlphaLISA immunoassay in stable COPD (n = 69) at baseline and at follow-up until 24 months after inclusion and in acute exacerbations of COPD (AECOPD) (n = 14) at baseline and until 6 months after inclusion.

RESULTS: The majority of patients (89%) were in GOLD II and III. Multiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p < 0.0001) and BODE index (p = 0.04). Negative associations were found with 6-min walking distance (p = 0.04) and bronchodilator-induced reversibility (p = 0.02). The pMFAP4 levels varied less than 25% between the baseline and a 3 month follow-up in 83% of the patients. The pMFAP4 levels appeared unaffected in the acute phase of severe AECOPD but rose to an increased stable level within one month after hospitalization.

CONCLUSION: Increased pMFAP4 was associated to the severity in COPD and has the potential to serve as a stable disease biomarker. This observation warrants confirmation in a larger longitudinal COPD population.

OriginalsprogEngelsk
TidsskriftRespiratory medicine
Vol/bind108
Udgave nummer9
Sider (fra-til)1336-44
Antal sider9
ISSN0954-6111
DOI
StatusUdgivet - sep. 2014

ID: 44962666